| Papers [1-15] of 37 :: [Page 1 of 3] | | Go to page : 1 2 3 —> | Search results on "MARKETING PFIZER": |
|
|
Marketing at Pfizer, 5.
An analysis of the success of the marketing campaigns used by Pfizer.
1,945 words (approx. 7.8 pages), 0 sources, MLA, $ 61.95
»
Click here to show/hide summary
Abstract
This paper presents an overview of the marketing used at pharmaceutical company, Pfizer. The paper begins with a description of the company's structure and, specifically, of the marketing department. The paper then looks at the specific strengths of this marketing, using Viagra as an example of a successful marketing campaign for a new product. Finally ,the paper mentions the threats that the company needs to be aware of in the market place.
From the Paper
"Pfizer is undeniably the most successful pharmaceutical company in existence. It rated first in U.S. sales from April 2002 through March 2003, with a total sales number of $20 billion USD, which accounted for 10% of the market share, and 12% growth. It ranked #1 ahead of GlaxoSmithKline, Johnson & Johnson, and Merck & Co., which took the second, third, and fourth spots, respectively. Much, if not most, of Pfizer?s success is due to the corporation?s marketing genius, which is considered to be among the best in the industry. Pfizer also has one of the best safety records in the industry, which helps in gaining investors and trust in the company."
| |
|
Marketing at Pfizer, 2008.
This paper discusses a marketing strategy to increase Pfizer growth in the intensely competitive and complex pharmaceutical industry.
1,330 words (approx. 5.3 pages), 6 sources, APA, $ 44.95
»
Click here to show/hide summary
Abstract
This paper explains that Pfizer has built a strong business around product development and product marketing that leaves its competitors at a disadvantage in their efforts to mimic its operations. The author points out that the Ansoff Matrix is an excellent tool to weigh various potential marketing strategies. The paper relates that ideally marketing strategies should be linked to overall corporate strategy and organizational objectives as outlined by the enterprise's executive leadership. The author indicates that another growth option is to expand organically from within Pfizer. The paper concludes that, because of Pfizer's success with Lipitor, which Pfizer markets worldwide, the company should continue to capitalize on this product by creating a generic Lipitor line extension. The author continues with an analysis of this marketing strategy.
Table of Contents:
Overview
Strategy Development
Ansoff's Growth Matrix
Synthesis of Objectives
Growth Strategies
Option One
Option Two
Target Market
Positioning
Product
Placement (Distribution)
Pricing
Promotion
Conclusion
From the Paper
"As soon as Pfizer is forced to go to market with its own generic version of Lipitor at reduced prices, the first year sales objective is to level Lipitor sales at $5-7 billion globally and to reach generic Lipitor sales of $3 to 5 billion. In so doing, the majority of Lipitor's research and development expenses will maintain substantial revenues. Current prices for Lipitor average $77 for a 30 day supply (Pfizer, 2005). The target price for the generic version should be $45 for a comparable supply."
| |
|
Pfizer's Marketing Strategy, 2008.
A research proposal about the marketing strategy of Pfizer, a major pharmaceutical industry competitor.
3,261 words (approx. 13.0 pages), 10 sources, APA, $ 93.95
»
Click here to show/hide summary
Abstract
This paper presents a proposal for a marketing strategy for the Pfizer pharmaceutical company that examines the competitive environment of the pharmaceutical industry within the context of Porter's five forces model and utilizes Merck as an illustrative competitor. The proposal explores whether Pfizer's marketing strategy is adequate for the present global environment and what possible strategic adjustments it could take to better position itself in the market. The proposal concludes with the inclusion of the academic base for the final research project.
Outline:
Background
Project Rationale
Reporting & Presentation
Timing
Proposal
From the Paper
"The need for the information related to this project arose because of the competitive nature of the pharmaceutical industry and Pfizer's need to remain market relevant. The organization and its executive management intend to leverage this information and data to result in a competitive advantage over the company's primary rivals in the industry. Although this research project focuses on a single company, Pfizer, and a primary competitor, Merck, its intent is to illustrate the importance and long-term necessity of developing evolutionary marketing strategies within a competitively restrictive environment."
| |
|
Pfizer Marketing Strategy, 2008.
A research proposal to discuss the marketing strategy of Pfizer, a major pharmaceutical industry competitor.
2,660 words (approx. 10.6 pages), 10 sources, APA, $ 79.95
»
Click here to show/hide summary
Abstract
The research examines the competitive environment of the pharmaceutical industry within the context of Porter's five forces model, utilizing Merck as an illustrative competitor. The paper discusses the problem statement that questions whether Pfizer's marketing strategy is adequate for the present global environment and what possible strategic adjustments it could take to better position itself in the market. The paper reveals the methodology to be used and concludes with the inclusion of the academic base for the final research project. The paper explains in an appendix why Pfizer is an excellent target enterprise for this research proposal.
Outline:
Executive Summary
Chapter 1: Background & Overview
Chapter 2: Research Objectives
Chapter 3: Methodology
Chapter 4: Presentation of Findings
Chapter 5: Conclusions & Recommendations
Proposed Time Schedule
From the Paper
"The pharmaceutical industry, as a sub-set of the medical and healthcare industry is highly competitive in nature. Additionally, it is a capital intensive industry relying heavily on research and development (R&D) without which its major competitors would not, and could not, bring new products to market. Yet, the marketing and distribution of these products is just as critical, if not more critical, than their development because programs must be developed to first create demand in the consumer market and then have the distribution network to deliver the products or products (Honeycutt, Ford & Simintiras, 2003, p.39)."
| |
|
Pfizer Marketing Strategy, 2008.
A research proposal for a study of Pfizer's marketing strategy.
3,280 words (approx. 13.1 pages), 10 sources, APA, $ 94.95
»
Click here to show/hide summary
Abstract
This proposal discusses the marketing strategy of a major pharmaceutical industry competitor, Pfizer. The competitive environment of the pharmaceutical industry is examined within the context of Porter's five forces model and Merck is utilized as an illustrative competitor. The problem statement questions whether Pfizer's marketing strategy is adequate for the present global environment and what possible strategic adjustments it could take to better position itself in the market. The theoretical research approach of the study is qualitative with a reliance on grounded theory, which argues that the research itself should not only validate or invalidate the hypothesis but that the research, conclusion, and recommendations should actually result in additional research hypotheses. This proposal concludes with the inclusion of the academic base for the final research project.
Outline:
Background
Project Rationale
Proposal
Objectives
Approach & Method
Reporting & Presentation
Recommendations
Timing
Fees/Cost Justification
From the Paper
"The need for the information related to this project arose because of the competitive nature of the pharmaceutical industry and Pfizer's need to remain market relevant. The organization and its executive management intend to leverage this information and data to result in a competitive advantage over the company's primary rivals in the industry. Although this research project focuses on a single company, Pfizer, and a primary competitor, Merck, its intent is to illustrate the importance and long-term necessity of developing evolutionary marketing strategies within a competitively restrictive environment. The pharmaceutical industry relies on constantly evolving marketing initiatives because the channels of distribution in the industry are evolving as well and how consumers are able to order and receive their medications is shifting from previous distribution models because of technology such as the internet and RFID technology (Rubin, 2004)."
| |
|
Pfizer's Marketing Strategy, 2004.
This paper examines the pharmaceutical giant Pfizer, a marketing powerhouse.
1,130 words (approx. 4.5 pages), 3 sources, MLA, $ 39.95
»
Click here to show/hide summary
Abstract
The paper discusses the pharmaceutical giant, Pfizer, as a marketing powerhouse. This report overviews some of its key products and tactics it uses in marketing them to consumers, physicians and managed care organizations.
From the Paper
"Marketing powerhouse Pfizer began back in ? as a chemicals company. Today it is a billion global enterprise and is one of the top pharmaceutical companies in the world. Pfizer's core products include Aricept Alzheimer's disease, Celebrex pain, Diflucan infection, Lipitor high cholesterol, Neurontin pain and epilepsy, Norvasc high blood pressure, Viagra erectile dysfunction, Xalatan glaucoma, Zithromax infection, Zoloft depression and Zyrtec allergy. The ultimate goal of Pfizer's marketing strategy is to increase drug sales which for prescription pharmaceuticals can only be accomplished by increased prescription writing."
| |
|
Pfizer Marketing, 2007.
This article examines the marketing strategy of the large pharmaceutical company, Pfizer.
2,714 words (approx. 10.9 pages), 14 sources, APA, $ 81.95
»
Click here to show/hide summary
Abstract
In this article, the writer provides a marketing audit that discusses the marketing strategy of a major pharmaceutical industry competitor: Pfizer. The competitive environment of the pharmaceutical industry is examined within the context of Porter's five forces model and Merck is utilized as an illustrative competitor. The writer questions whether Pfizer's marketing strategy is adequate for the present global environment and what possible strategic adjustments it could take to better position itself in the market. The theoretical research approach of the study is qualitative with a reliance on grounded theory which argues that the research itself should not only validate or invalidate the hypothesis but that the research, conclusion, and recommendations should actually result in additional research hypotheses.
Table of Contents:
Executive Summary
Table of Contents
Environmental Considerations
Markets
Summary conclusion
Competition
Summary conclusion
Economics
Summary conclusion
Marketing Considerations
Strategies
Summary conclusion
Market Tactics
Summary conclusion
The 4 Ps
Conclusion
References
From the Paper
"Porter identifies five levels of competition that most enterprises face in today's hyper-competitive marketplace: direct, close, similar products, substitute products and indirect competition. These levels of competition comprise Porter's five forces model of competition whereby he models the relationship in the marketplace between competitive forces that together form a core of rivalry that is measured in degrees of intensity. For the pharmaceutical industry, the degree of intensity in competitive forces is extremely high because the risks at stake are considerable; often in the 100s of millions to the billions. These large stakes are due to the nature of the industry where huge sums of money must be spent to simply discover new products, while additional huge sums then must be committed to develop them, seek regulatory approval and then actively market them .."
| |
|
Pfizer and the World Market, 2002.
Analysis of pharmaceutical company Pfizer Inc.
2,900 words (approx. 11.6 pages), 19 sources, $ 106.95
»
Click here to show/hide summary
Abstract
This paper looks at The Control Problems of a Global Firm, in this case it is the pharmaceutical company Pfizer Inc. discussing what problems they have encountered whilst maintaining its global presence and business, such as Global Currency Difficulties, Global Research & Development including the difference in regulations from region to region and finally their Global Drug Marketing and Sales procedures.
| |
|
Pfizer Pharmaceutical Company, 2004.
An analysis of the marketing success of the Pfizer Pharmaceutical Company.
1,938 words (approx. 7.8 pages), 6 sources, MLA, $ 61.95
»
Click here to show/hide summary
Abstract
This paper examines how Pfizer is one of the most successful pharmaceutical companies in existence and how much, if not most, of Pfizer?s success is due to the corporation?s marketing genius, which is considered to be among the best in the industry. It looks at how Pfizer also has one of the best safety records in the industry, which helps in gaining investors and trust in the company. It also explores how, unlike most large corporations, Pfizer draws revenue from a limited number of products.
Outline
Company Structure and Marketing Strategies
Marketing Strengths
Threats
From the Paper
"The marketing principles utilized by Pfizer guides every aspect of the corporation?s business. There are five main principles that are fundamental to Pfizer?s business practices. First, the work conducted by Pfizer is grounded in science. With solid clinical research as a foundation, Pfizer?s marketing group uses its credibility and knowledge to develop important relationships within the medical community. Second, Pfizer takes an integrated approach to its marketing strategies. Innovation is promoted through the encouragement of teamwork within and across marketing groups. This also allows Pfizer to respond flexibly and promptly to changes in the market."
| |
|
Organizational Growth at Pfizer, 2008.
A discussion of the organizational growth of the Pfizer pharmaceutical company, through an analysis of the company's planning and marketing strategy.
1,605 words (approx. 6.4 pages), 6 sources, APA, $ 52.95
»
Click here to show/hide summary
Abstract
This paper takes a look at how the pharmaceutical company Pfizer has been quite effective at utilizing marketing strategy based market development to expand its revenue streams and extend the useful life of its existing products. The paper maintains that Pfizer's sales and marketing division is one of the drug industries best and has been a strong contributor to creating one of the most pathological advertising establishments in the United States. The paper uses the Ansoff matrix as a tool to assess Pfizer's marketing strategies in relation to the general drug market. The paper concludes that Pfizer owes its success to its vast resources, global distribution and channel technology, and brand equity.
Outline:
Introduction
Gap Analysis
Ansoff's Matrix-Strategic Planning
Recommended Solutions
Conclusion
From the Paper
"There are several strategies to accomplish growth. One of the easiest from an operational standpoint is to simply acquire or merge with another company which is inline with Ansoff's market or product development strategy. The exact nature of the strategy is dependent upon the character of the businesses being acquired or merged with. Mergers and acquisitions (M&A) provide companies with an instant expanded market and a new product or product line as well as, potentially, a completely new industry. If the M&A target is a company that focuses on a different market or market segment this would be a strategy based on market development because the primary company would be moving into what is, in effect, according to Ansoff, a new market."
| |
|
Merck and Pfizer Inc., 2002.
A marketing analysis of the pharmaceutical companies Pfizer Inc. and Merck.
3,314 words (approx. 13.3 pages), 12 sources, MLA, $ 94.95
»
Click here to show/hide summary
Abstract
This paper provides an insight into the two pharmaceutical companies Pfizer Inc. and Merck with an emphasis on their marketing strategies. It outlines the companies? products, services and position in their industry and then provides a comparative analysis using the four Ps of marketing.
Outline
Introduction
Company Analysis - Pfizer Inc.
Line of Business and Sales and Profit Trends
The Specific Target Market(S) Sought
Company Brands, Manner of Distribution, Promotion Methods and Pricing
The Differential Advantages/Strengths of the Firm
International Performance
Company Analysis - Merck
Line of Business and Sales and Profit Trends
The Specific Target Market(S) Sought
Company Brands, Manner of Distribution, Promotion Methods and Pricing
The Differential Advantages/Strengths of the Firm
International Performance
Comparison
Web Sites
Describe Each Site
Strengths and Weaknesses of Each Site
Specific Sections
Improvement of Both the Sites
Conclusion
Bibliography
Appendix
From the Paper
"Unlike other firms, Pfizer's main business focus had been to improve its products and to extend its product line. Over the years, analysts find that Pfizer has spent much more on currency of its research and development as compared to business development and strategy. For example one analyst comments on Pfizer's strategy: "McKinnell is one of the primary architects of the acquisition strategy that has supercharged Pfizer's growth. So it's startling to hear him argue that the company's acquisition days are over. Despite the fact that Pfizer commands only 11% of the global pharmaceutical market, its growth, he declares, now lies in R&D, not M&A. "This Company?s future will be quite different," McKinnell says. "People tend to evaluate research looking out the back window, not the front. And the '90s were really unusual." [Simons, 2003]. For this reason it has leverage over other companies. However with the emergence of new prescription drugs and mandates in biomedical fields other companies like Merck, Pharmacia as well as Eli Lilly have been focusing their investments in these areas as well [See Appendix]. "
| |
|
Pfizer's Growth Strategy, 2008.
An organizational growth study, with Pfizer as the target company.
1,333 words (approx. 5.3 pages), 6 sources, APA, $ 44.95
»
Click here to show/hide summary
Abstract
This paper discusses how Pfizer has developed a very integrated manufacturing and distribution network that has allowed it to capitalize on its brand image as a leading pharmaceutical company. The paper labels Pfizer's sales and marketing division as one of the best in the industry. The paper concludes that because of Pfizer's success with Lipitor, which it markets worldwide, the company should continue to capitalize on this product by creating a generic Lipitor line extension.
Outline:
Overview
Strategy Development
Ansoff's Growth Matrix
Synthesis of Objectives
Growth Strategies
Conclusion
From the Paper
"For the pharmaceutical industry, the intensity of the competitive forces at play is extremely high because the risks at stake are considerable. These large stakes are due to the nature of the industry where huge sums of money must be spent to simply discover new products, while additional huge sums then must be committed to develop them, seek regulatory approval, and then actively market them (Miller, 2003, para.3). With such huge sums of investment dollars required for almost every product brought to market, the competitive forces surrounding the industry are extreme."
| |
|
Pfizer Inc., 2005.
A review of Pfizer Inc., one of the largest pharmaceutical companies in the USA.
675 words (approx. 2.7 pages), 0 sources, $ 26.95
»
Click here to show/hide summary
Abstract
This paper analyzes the US medical giant, Pfizer Inc. According to this paper, Pfizer Inc. is one of the leading pharmaceutical companies in the U.S. This paper reviews the company's place in the industry and their stock dividends.
From the Paper
"Pfizer is a U.S. based pharmaceutical company, which opened its doors 156 years ago in 1849 with a compound that was proven to take care of parasitic worms. There were two co-founders, Charles Pfizer and his cousin Charles Erhart. Both had come from Germany in the hopes of starting a business together. They had no idea that what they would leave behind would end up being one of the largest pharmaceutical companies in the nation ("Exploring our History", 2005). Industry Analysis Pfizer participates in an industry coded and named by the United States Department of Labor. As such they do business in Division D: Manufacturing - Major Group 28: Chemicals and Allied Products. Specifically Pharmaceutical Preparation coded 2834. Any company in this category produces, manufactures, "fabricates or processed pharmaceutical drugs in preparation for human or veterinary consumption" ("SIC Description for 2834", 2005)."
| |
|
Case Study: Pfizer Enterprise Risk Management, 2008.
Looks at enterprise risk management (ERM) at Pfizer from the viewpoint of the Sarbanes-Oxley financial reporting requirements.
1,185 words (approx. 4.7 pages), 6 sources, APA, $ 40.95
»
Click here to show/hide summary
Abstract
This paper discusses enterprise risk management from the viewpoint of new financial reporting requirements in the corporate world, specifically those associated with Sarbanes-Oxley legislation in the United States. Additionally, this brief implementation plan discusses enterprise risk management from the perspective of a single company: Pfizer. Pfizer scale and scope of operations ensures that it requires the most comprehensive of plans. Additionally, the particular enterprise risk management planning strategy employed is the COSO framework.
Table of Contents:
Abstract
Company Overview
COSO and Sarbanes Oxley
COSO
Sarbanes-Oxley
Implementation Framework
Control Environment
Risk Assessment
Control Activities
Information and Communication
Monitoring
From the Paper
"Pfizer's executive leadership should identify financial reporting objectives with sufficient clarity and specificity to enable the identification of risks to reliable financial reporting. Pfizer should identify and analyze risks that are associated with preventing the achievement of financial reporting objectives as a basis for determining how the risks should be managed. The potential for possible financial misstatement due to fraudulent reporting should be incorporated when assessing risks to the achievement of financial reporting objectives with the company."
| |
|
Pfizer, Inc. and the Pharmaceutical Industry, 2005.
This paper is a risk analysis of Pfizer, Inc. and the pharmaceutical industry including its direct competitors: Bayer AG, Merck & Co., Novartis AG, Abbott Labs and Eli Lilly.
2,175 words (approx. 8.7 pages), 7 sources, MLA, $ 67.95
»
Click here to show/hide summary
Abstract
This paper explains that Pfizer and all five of its direct competitors essentially face many of the same risks such as the tendency for the marketplace to discourage the use of new medicines because of their higher costs. The author points out that the safety of products and proper usage by consumers are always concerns as demonstrated by the problems facing Bayer and Merck and, now, potentially, by Pfizer with Celebrex. The paper concludes that Pfizer is unique from its competitors and remains the leading pharmaceutical company because of its effective risk and resource management of the company's extraordinary portfolio management practices, security of the day-to-day management of resources and its research and development.
From the Paper
"The third goal, corporate social responsibility, means putting people and communities first and preserving and protecting the environment. It also means being sensitive to the needs of Pfizer's colleagues, and evaluating the company from a critical point of view. Over the past four years, Pfizer has almost tripled in size, from about 45,000 colleagues worldwide to over 122,000. In 2003, Pfizer created a global corporate citizenship coordinating team. The goal of this group is to help unify Pfizer's approach to corporate citizenship across many countries and cultures, through membership in organizations that promote responsible business practices internationally. Some of the initiatives that have been explored are the reduction of carbon monoxide emissions and supplying global energy through cleaner sources. This final goal is a symbol of Pfizer's commitment to strengthen leadership and become more responsive."
|
|
|
